Inhaled corticosteroids in COPD: Personalising the therapeutic choice

Area of Science:

• Pulmonology
• Respiratory Medicine
• Pharmacology

Background:

• Chronic obstructive pulmonary disease (COPD) is a major global health issue characterized by persistent respiratory inflammation.
• Inhaled corticosteroids (ICS) are established treatments, but their role in COPD, particularly in relation to eosinophilic phenotypes, is under active investigation.
• Current guidelines restrict ICS use to severe COPD cases, prompting a re-evaluation of their broader applicability.

Purpose of the Study:

• To review the current evidence on the efficacy and safety of inhaled corticosteroids (ICS) in the management of COPD.
• To explore the potential benefits of ICS in reducing exacerbation rates and controlling inflammation across the spectrum of COPD severity.
• To assess the role of ICS in COPD patients, considering specific phenotypes like those with high eosinophil counts.

Main Methods:

• Systematic review of existing literature and clinical trial data.
• Analysis of evidence regarding ICS impact on COPD exacerbations and inflammatory markers.
• Evaluation of safety profiles, including localized adverse effects and pneumonia risk associated with ICS use.

Main Results:

• Inhaled corticosteroids (ICS) demonstrate efficacy in reducing COPD exacerbation frequency.
• Evidence suggests ICS play a role in managing the underlying inflammation central to COPD pathogenesis.
• While ICS use is associated with increased localized side effects and a slight rise in pneumonia risk, these are often outweighed by benefits in exacerbation reduction.

Conclusions:

• Inhaled corticosteroids (ICS) may offer benefits beyond severe COPD, potentially for all patients.
• The anti-inflammatory and exacerbation-reducing properties of ICS remain significant for COPD management.
• A nuanced approach to ICS use in COPD is warranted, considering individual patient characteristics and risk-benefit profiles.